The effect of rosiglitazone is similar to that reported for lifestyle changes.
Among patients at risk for progression to diabetes, metformin and acarbose therapy each modestly reduce the likelihood of progression; dietary modifications and increased exercise are more effective but are also more difficult to maintain (Journal Watch Feb 19 2002). In a new industry-funded multinational trial, researchers explored the effectiveness of rosiglitazone, ramipril, or both in patients at risk for diabetes; ramipril was studied because angiotensin-converting–enzyme inhibitors have been associated with a lower incidence of diabetes in previous trials (done for other purposes).
Researchers randomized more than 5000 nondiabetic patients with either elevated fasting glucose levels (110–125 mg/dL) or impaired glucose tolerance (plasma…